{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T07:35:00Z","timestamp":1771918500053,"version":"3.50.1"},"reference-count":15,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,9,22]],"date-time":"2021-09-22T00:00:00Z","timestamp":1632268800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Immune checkpoint inhibitors have brought long-term survival benefit in advanced non-small cell lung cancer patients without driver gene mutations. Even after withdrawal of immunotherapy for a maximum of two years, some patients still benefit from this therapy and the reason is not fully clear. Results from several neoadjuvant trials indicated that in resectable lung cancer patients, neoadjuvant immunotherapy or chemo-immunotherapy led to major or complete pathological responses in a high proportion of tumors. Here we report a case of a brain-metastatic lung squamous cell carcinoma patient who received supratentorial tumor resection and thoracic surgery after chemo-immunotherapy, and achieved a pathological complete response (pCR) in both lesions. This case indicated that pCR can also happen in advanced-stage lung cancer patients receiving chemo-immunotherapy, which may be the reason for long-term benefit of those patients.<\/jats:p>","DOI":"10.3389\/fonc.2021.693704","type":"journal-article","created":{"date-parts":[[2021,9,22]],"date-time":"2021-09-22T13:27:13Z","timestamp":1632317233000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Case Report: Pathological Complete Response in a Brain-Metastatic Lung Squamous Cell Carcinoma Patient With Long-Term Benefit From Chemo-Immunotherapy"],"prefix":"10.3389","volume":"11","author":[{"given":"Chen","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nengsheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuo","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuai","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minrui","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Pang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,9,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.06.015","article-title":"A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407","volume":"15","author":"Paz-Ares","year":"2020","journal-title":"J Thorac Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.3244996","article-title":"Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced Non-Small Cell Lung Cancer: CheckMate 078 Randomized Phase III Clinical Trial","volume":"14","author":"Wu","year":"2019","journal-title":"J Thorac Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab Plus Chemotherapy in Metastatic Non\u2013Small-Cell Lung Cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30453-8","article-title":"Neoadjuvant Chemotherapy and Nivolumab in Resectable Non-Small-Cell Lung Cancer (NADIM): An Open-Label, Multicentre, Single-Arm, Phase 2 Trial","volume":"21","author":"Provencio","year":"2020","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0236","article-title":"An Accurate and Comprehensive Clinical Sequencing Assay for Cancer Targeted and Immunotherapies","volume":"24","author":"Cao","year":"2019","journal-title":"Oncologist"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1038\/s41467-019-08887-7","article-title":"The Aryl Hydrocarbon Receptor Mediates Tobacco-Induced PD-L1 Expression and Is Associated With Response to Immunotherapy","volume":"10","author":"Wang","year":"2019","journal-title":"Nat Commun"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.oooo.2019.07.008","article-title":"Association of PD-L1 Expression in Oral Squamous Cell Carcinoma With Smoking, Sex, and P53 Expression","volume":"128","author":"Ahmadi","year":"2019","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djab116","article-title":"Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer","author":"Wang","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.06.020","article-title":"Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With Non-Small-Cell Lung Cancer and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, 189, and 407","author":"Powell","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-020-04711-3","article-title":"The Efficiency of 18F-FDG PET-CT for Predicting the Major Pathologic Response to the Neoadjuvant PD-1 Blockade in Resectable Non-Small Cell Lung Cancer","volume":"47","author":"Tao","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-2020-63","article-title":"Expert Consensus on Neoadjuvant Immunotherapy for Non-Small Cell Lung Cancer","volume":"9","author":"Liang","year":"2020","journal-title":"Trans Lung Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.8504","article-title":"Neoadjuvant Nivolumab (N) or Nivolumab Plus Ipilimumab (NI) for Resectable Non-Small Cell Lung Cancer (NSCLC): Clinical and Correlative Results From the NEOSTAR Study","volume":"37","author":"Cascone","year":"2019","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716078","article-title":"Neoadjuvant PD-1 Blockade in Resectable Lung Cancer","volume":"378","author":"Forde","year":"2018","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.11.499","article-title":"MA15.03 The Predictive Value of Mutation\/Neoantigen Burden From ctDNA on the Efficacy of PD-1 Blockade in Advanced NSCLC","volume":"12","author":"Cai","year":"2017","journal-title":"J Thorac Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.0412","article-title":"Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non\u2013Small-Cell Lung Cancer: Results From the CA209-003 Study","volume":"36","author":"Gettinger","year":"2018","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.693704\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T13:41:43Z","timestamp":1632750103000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.693704\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,22]]},"references-count":15,"alternative-id":["10.3389\/fonc.2021.693704"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.693704","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,22]]},"article-number":"693704"}}